Screener
Spyre Therapeutics, Inc. SYRE Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001636282-26-000050
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Series B non-voting convertible preferred stock, $0.0001 par value; 271,625 shares authorized and 16,667 shares issued and outstanding as of March 31, 2026 and December 31, 2025. | 9,395 | 9,395 |
| Preferred stock, $0.0001 par value; 8,642,034 shares authorized as of March 31, 2026 and December 31, 2025; no shares issued and outstanding as of March 31, 2026 and December 31, 2025. | — | — |
| Common stock, $0.0001 par value; 400,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 78,839,858 shares and 78,189,811 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively. | 15 | 15 |
| Additional paid-in capital | 1,712,383 | 1,686,167 |
| Accumulated other comprehensive (loss) income | (767) | 869 |
| Accumulated deficit | (1,196,640) | (1,127,635) |
| TOTAL STOCKHOLDERS’ EQUITY | 670,811 | 715,236 |
| TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY | $763,953 | $777,781 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Spyre Therapeutics, Inc.'s total liabilities & equity?
- Spyre Therapeutics, Inc. (SYRE) reported total liabilities & equity of $763.95M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s total liabilities & equity changed year-over-year?
- Spyre Therapeutics, Inc.'s total liabilities & equity increased by 34.1% year-over-year, from $569.78M to $763.95M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s total liabilities & equity?
- Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s total liabilities & equity has grown at a 36.9% compound annual growth rate (CAGR), from $161.62M to $777.78M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about Spyre Therapeutics, Inc.'s total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude